Market Currents
More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M,...
-
Tuesday, February 26, 4:35 PM ETMore on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M, compared to net sales of $71.8M for Q411. Gross margin was 85.8% compared to 95.2% for 2011. For FY13, the company expects an EPS of $5.70-5.90 on sales of $805M - 835M, above Street estimates of $5.67 on revenue of $811.3M. Shares +2% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
